Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $16.94 in the prior trading day, Zymeworks BC Inc (NASDAQ: ZYME) closed at $16.68, down -1.51%. In other words, the price has decreased by -$1.51 from its previous closing price. On the day, 0.71 million shares were traded. ZYME stock price reached its highest trading level at $17.4 during the session, while it also had its lowest trading level at $16.625.
Ratios:
Our goal is to gain a better understanding of ZYME by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.69 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 16, 2024, JP Morgan Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $18.
Leerink Partners Upgraded its Market Perform to Outperform on November 07, 2024, whereas the target price for the stock was revised from $10 to $25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 15 ’25 when EcoR1 Capital, LLC bought 49,502 shares for $11.43 per share. The transaction valued at 565,847 led to the insider holds 17,877,989 shares of the business.
EcoR1 Capital, LLC bought 5,919 shares of ZYME for $69,738 on May 19 ’25. The Director now owns 17,883,908 shares after completing the transaction at $11.78 per share. On Apr 16 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 73,953 shares for $11.16 each. As a result, the insider paid 825,589 and bolstered with 17,773,727 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1263644800 and an Enterprise Value of 991446976. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.28 while its Price-to-Book (P/B) ratio in mrq is 3.76. Its current Enterprise Value per Revenue stands at 8.069 whereas that against EBITDA is -13.655.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.47, which has changed by 0.33160412 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $9.03. The 50-Day Moving Average of the stock is 12.76%, while the 200-Day Moving Average is calculated to be 24.48%.
Shares Statistics:
The stock has traded on average 503.01K shares per day over the past 3-months and 646350 shares per day over the last 10 days, according to various share statistics. A total of 74.85M shares are outstanding, with a floating share count of 73.13M. Insiders hold about 3.44% of the company’s shares, while institutions hold 101.16% stake in the company. Shares short for ZYME as of 1757894400 were 7156267 with a Short Ratio of 14.23, compared to 1755216000 on 6807564. Therefore, it implies a Short% of Shares Outstanding of 7156267 and a Short% of Float of 12.0900005.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of Zymeworks BC Inc (ZYME) in the stock market.The consensus estimate for the next quarter is -$0.19, with high estimates of $0.36 and low estimates of -$0.62.
Analysts are recommending an EPS of between $0.01 and -$1.42 for the fiscal current year, implying an average EPS of -$0.79. EPS for the following year is -$1.44, with 7.0 analysts recommending between -$0.04 and -$2.04.
Revenue Estimates
5 analysts predict $34.5M in revenue for. The current quarter. It ranges from a high estimate of $53.6M to a low estimate of $19M. As of. The current estimate, Zymeworks BC Inc’s year-ago sales were $16MFor the next quarter, 5 analysts are estimating revenue of $50.43M. There is a high estimate of $93.6M for the next quarter, whereas the lowest estimate is $26M.
A total of 7 analysts have provided revenue estimates for ZYME’s current fiscal year. The highest revenue estimate was $200.2M, while the lowest revenue estimate was $95.9M, resulting in an average revenue estimate of $146.95M. In the same quarter a year ago, actual revenue was $76.3MBased on 8 analysts’ estimates, the company’s revenue will be $135.73M in the next fiscal year. The high estimate is $313.26M and the low estimate is $43.6M.
